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cells induce apoptosis in PC-3 prostate cancer
cells through activation of JNK and
downregulation of PI3K/AKT signaling
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Introduction: Although mesenchymal stem cells (MSCs) have antitumor potential in hepatocellular carcinoma and
breast cancer cells, the antitumor mechanism of human umbilical cord mesenchymal stem cells (hUCMSCs) in
prostate cancer cells still remains unclear. Thus, in the present study, we elucidated the antitumor activity of
hUCMSCs in PC-3 prostate cancer cells in vitro and in vivo.
Methods: hUCMSCs were isolated from Wharton jelly of umbilical cord and characterized via induction of
differentiations, osteogenesis, and adipogenesis. Antitumor effects of UCMSCs on tumor growth were evaluated in
a co-culture condition with PC-3 prostate cancer cells. PC-3 cells were subcutaneously (sc) injected into the left flank
of nude mice, and UCMSCs were sc injected into the right flank of the same mouse.
Results: We found that hUCMSCs inhibited the proliferation of PC-3 cells in the co-culture condition. Furthermore,
co-culture of hUCMSCs induced the cleavage of caspase 9/3 and PARP, activated c-jun NH2-terminal kinase (JNK), and
Bax, and attenuated the phosphorylation of phosphatidylinositol 3-kinase (PI3K)/ AKT, extracellular signal-regulated kinase
(ERK), and the expression of survival genes such as Bcl-2, Bcl-xL, Survivin, Mcl-1, and cIAP-1 in PC-3 cells in Western blotting
assay. Conversely, we found that treatment of specific JNK inhibitor SP600125 suppressed the cleavages of caspase 9/3
and PARP induced by hUCMSCs in PC-3 cells by Western blotting and immunofluorescence assay. The homing of
hUCMSCs to, and TUNEL-positive cells on, the K562 xenograft tumor region were detected in Nu/nu-BALB/c mouse.
Conclusions: These results suggest that UCMSCs inhibit tumor growth and have the antitumor potential for PC-3
prostate cancer treatment.Introduction
Although clinical use of stem cells has been applied to vari-
ous diseases, such as leukemia [1,2], Parkinson disease [3,4],
diabetes [5], stroke [6], and cardiac disease [7-10], still limi-
tations of their clinical use exist because of tumor-formation
risk, host immune rejection, and ethical issues. However,
mesenchymal stem cells (MSCs) are attractive compared
with embryonic stem cells as a substitute resource for clin-
ical use [11]. MSCs, also known as stromal progenitor* Correspondence: sungkim7@khu.ac.kr
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unless otherwise stated.cells, are found in several places in the human body, such
as bone marrow, umbilical cord, umbilical cord blood,
placenta, and muscle synovial membrane [12]. Under ap-
propriate culture conditions, MSCs have the potential for
self-renewal and differentiation into various cell lineages for
osteocytes, adipocytes, and chondrocytes [13].
Recently, human umbilical cord blood (UCB) or human
umbilical cord tissue mesenchymal cells (hUCMSCs), iso-
lated from fetal origins, have been studied for clinical use
because UCMSCs are considered to be a more-primitive
precursor than MSCs [14,15]. Also, the umbilical cord
matrix is suggested as a better source for the MSCs than
umbilical cord blood in respect of higher expansion po-
tential [16]. The hUCMSCs were known to express spe-
cific surface markers, such as CD44, CD105 (adhesion. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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CD105 (mesenchymal stem cell markers), but not
hematopoietic lineage markers, such as CD34, CD45, and
HLA-class II [17-19]. Also, hUCMSCs have an immune-
suppressive effect or reduced immunogenicity [20] and
express vascular endothelial growth factor (VEGF) and
interleukin (IL)-6 [18,21]. Recently, UCB-derived MSCs
showed cytotoxicity against glioma [22] and Kaposi sar-
coma [23], and umbilical cord mesenchymal stem cells
suppressed the growth of breast cancer cells [24-26].
Based on previous evidence, in the present study, we in-
vestigated the antitumor mechanism of hUCMSCs in PC-
3 prostate cancer cells and report that hUCMSCs induce
antiproliferative and apoptotic effects in PC-3 cells via ac-
tivation of JNK and inhibition of the PI3K/AKT pathway
in either direct or indirect culture conditions.
Materials and methods
Culture for PC-3 prostate cancer cells and hUCMSCs
PC-3 prostate cancer cells were obtained from the
American Type Culture Collection (ATCC, Rockville,
MD, USA) and maintained in RPMI1640 containing 10%
heat-inactivated fetal bovine serum (FBS) (Invitrogen,
Carlsbad, CA, USA) and standard antibiotics (Invitro-
gen). In contrast, umbilical cord (UC) specimens were
obtained within an hour of surgical resection under
Kyung Hee Medical Center IRB-approved (KMC IRB
1125–03) just after appropriate written consent for the
use of the human umbilical cord tissues.
Human UCMSCs were isolated from UCs of full-term
delivery patients, as previously described [27]. In brief,
UCs were washed in calcium, magnesium-free phosphate-
buffered saline (DPBS), and cut into 1- to 2-mm3 pieces.
Samples were enzymatically digested for 1 hour at 37°C
with 3 mg/ml of collagenase type I (Sigma-Aldrich, St.
Louis, MO, USA). Cells were filtered through a 40-μm
nylon cell strainer and centrifuged at 1,500 rpm for 5 mi-
nutes, and pellets were collected as hUCMSCs. The cells
were plated in 100-mm tissue-culture dishes at a density
of 1 × 104 cells/cm2 for growth at 37°C in a humidified
5% CO2 atmosphere in low-glucose Dulbecco modified
Eagle medium (Invitrogen) with fibroblast growth factor
(FGF)-2 (Sigma), insulin (Invitrogen), antibiotic solution
(100 μg/ml penicillin, and 100 μg/ml streptomycin; Invi-
trogen), 1% gentamycin (Sigma), and heat-inactivated FBS
(Invitrogen). Adherent cells were detached by incubation
for 5 minutes with trypLE-Express (Invitrogen) and then
replated at the same density.
Osteogenic and adipogenic differentiation assays
Differentiation was induced according to established proto-
cols [28]. In brief, for osteogenic differentiation, hUCMSCs
were cultured to 80% to 90% confluency for 14 days
in DMEM-LG supplemented with 10% FBS, 100 nMdexamethasone, 200 μM ascorbic acid 2-phosphate, and
10 mM β-glycerophosphate. Alizarin Red staining was per-
formed in subconfluent hUCMSCs for the visualization of
calcium deposition. Cells were fixed with 4% paraformalde-
hyde for 10 minutes at room temperature, washed, stained
with Alizarin Red staining solution for 1 hour in the dark,
washed with 1 ml distilled water, and added by PBS. For in-
duction of adipogenic differentiation, hUCMSCs were
cultured to 80% to 90% confluence. Adipogenic differenti-
ation media consisting of DMEM high glucose (Lonza)
supplemented with 10% FCS, PSG, 10−6M dexamethasone,
0.2 mM indomethacin, 0.1 mg/ml insulin, and 1 mM
3-isobutylmethylxanthine (Sigma-Aldrich) were changed
twice a week for 14 days. The differentiated cells were fixed
with 4% formaldehyde and stained with Oil Red O (Sigma-
Aldrich) to visualize lipid vacuoles. The red lipid images
were observed under phase-contrast microscope.
Cytotoxicity assay
Cytotoxic effects of hUCMSCs against PC-3 cells were
evaluated by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. We cocultured PC-3
cells by using Transwell assay system along with several
densities of hUCMSCs for 24 hours in the same culture
condition as hUCMSCs. The cells were incubated with 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (1 mg/ml) (Sigma Chemical Co., St. Louis, MO, USA)
for 2 hours and then with MTT lysis solution overnight.
Optical density (OD) was measured by using a microplate
reader (Molecular Devices Co., Sunnyvale, CA, USA) at
570 nm. Cell viability was calculated as a percentage
of viable cells cocultured with hUCMSCs versus single
cultured control.
Proliferation assay
DNA synthesis was detected by using a colorimetric bro-
modeoxyuridine (BrdU)-based Cell Proliferation ELISA
kit (Roche Molecular Biochemicals, Mannheim, Germany)
by following manufacturer’s instructions. In brief, we culti-
vated PC-3 cells by using Transwell assay system along
with several densities of hUCMSCs in the same culture
condition as hUCMSCs. For growing purposes, they were
labeled with BrdU for 48 hours, as previously described
[29]. The absorbance was measured at 450 nm by micro-
plate reader (Tecan, Austria). Culture medium was used
as a control for nonspecific binding.
Immunoblotting analysis
Immunoblotting was done according to our standard pro-
tocols, as described previously [29]. The protein samples
were extracted, quantified, and separated on SDS-PAGE
gels and electro-transferred to nitrocellulose membranes.
Nitrocellulose membranes were blocked in 5% nonfat milk
and incubated with primary antibodies for PARP, BAX,
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USA), cleaved caspase 9, Bcl-2, Bcl-xL, p-ERK, p-AKT,
p-JNK (Cell Signaling Technology, Danvers, MA, USA)
and β-Actin (Sigma). The blots were then exposed to
HRP-conjugated secondary mouse or rabbit antibodies
and analyzed by using enhanced chemiluminescence (ECL)
Western blotting detection system (GE HealthCare
Bio-Sciences, Piscataway, NJ, USA).
Inoculation of PC-3 cells and hUCMSCs in mice
Nu/nu-BALB/c mice (4 to 5 weeks old) were purchased
from the Shizuoka Laboratory Center (Kotoh, Japan)
and maintained under classic conditions (55% relativeFigure 1 Characterization of mesenchymal stem cells. (A) Beta-galacto
(0, 1, 3, and 5) of hUCMSCs. Cell morphology was observed by phase-contr
according to the passages of hUCMSCs. (C) Characterization of isolated hU
and NANOG (red). Nuclei were stained with DAPI (blue). Scale bar, 50 μm. (
osteogenic differentiation media for 14 days was performed by identificatio
in Materials and Methods. The cells were stained with Oil Red-O and Alizarhumidity and 22°C ± 2°C). PC-3 cells and hUCMSCs
were harvested and washed with 0.1 ml PBS. The cells
gently were mixed with equal amount of growth factor-
reduced Matrigel (BD BioSciences, San Jose, CA, USA)
on ice. PC-3 cells (2 × 106) were subcutaneously trans-
planted into the left flank of mice, and, 2 weeks later,
hUCMSCs (5 × 106) stained with PKH26 dye (Sigma)
were transplanted into the right flank of mice. Eight
weeks after PC-3 cell inoculation, Matrigel plugs were
isolated from mice for H&E, immunohistochemistry,
and TUNEL assay. The immunofluorescence staining
image for PKH26 dye stained hUCMSCs in PC-3 cell
tumor section was visualized under an Axio vision 4.0sidase staining was used to check SA-β-gal activity in early passages
ast microscopy. Scale bar, 50 μm. (B) Growth kinetics of the hUCMSCs
CMSCs was performed by identification of MSC markers, OCT4 (green)
D) Characterization of isolated hUCMSCs cultured in adipogenic and
n of the adipogenic and osteogenic differentiation assays, as described
in Red dye staining, respectively. Scale bar, 100 μm.
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Germany). This study was approved by and conducted
in accordance with the policies set forth by the Animal
Care and Use Committee of Kyung Hee University (Ref
IRB; KHUASP(SE)-11–005).Terminal deoxynucleotidyltransferase dUTP nick-end
labeling (TUNEL) assay
DNA fragmentation was analyzed by using Dead End
fluorometric TUNEL assay kit (Promega, Madison, WI,
USA). The tissues were fixed in 4% methanol-free formal-
dehyde solution in PBS for 35 minutes at 4°C and treated
with terminal deoxyribonucleotidyltransferase (TdT) en-
zyme buffer containing fluorescein-12-dUTP for 1 hour at
37°C in the dark. The slides were mounted with mounting
medium containing 4′,6-diamidino-2-phenylindole (DAPI)
(Vector, Burlingame, CA, USA) and visualized under an
Axio vision 4.0 fluorescence microscope (Carl Zeiss).Figure 2 The inhibitory effect of hUCMSCs on prostate cancer cell gro
were cocultured for 24 hours with or without hUCMSCs at ratio of 1:10, 1:5
Transwell chamber, and different numbers of hUCMSCs (hUCMSCs:PC-3s, 1
on the viability of PC-3 cells by MTT assay. (B) Effect of hUCMSCs on the p
PC-3 cells cocultured with hUCMSCs by phase-contrast microscopy. **P < 0Statistical analysis
Statistical analysis was performed by using Microsoft
Excel analysis tools and SigmaPlot 2001 software. All
data values are shown as means ± standard deviation
(SD). The statistical significance was analyzed by using
the Student t test and analysis of variance. P values
of <0.05 were considered statistically significant.
Results
Characterizations of MSCs isolated from umbilical cord tissues
Regular morphology of isolated MSCs from umbilical
cord (UC) was observed under phase-contrast micros-
copy, and very rare SA-β-gal-positive senescent cells
were found in passages 0, 1, 3, and 5 of hUCMSCs by
β-galactosidase assay (Figure 1A) [30]. As shown in
Figure 1B, the normal proliferation rate of isolated MSCs
was also confirmed (Figure 1B).
Taken together, early passages of hUCMSCs are appro-
priate to use in this study. Porcine umbilical cord matrixwth in direct or indirect coculture condition. PC-3 cells (5 × 104)
, and 1:3 (hUCMSCs:PC-3s). PC-3 cells were placed in the lower
:10, 1:5, 1:3) were seeded in the upper chamber. (A) Effect of hUCMSCs
roliferation of PC-3 cells by BrdU assay. (C) Analysis of morphology of
.01, ***P < 0.001 versus untreated control.
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scription markers such as OCT4, NANOG, and Sox
[31]. Therefore, the expression of these MSC markers
was evaluated in isolated hUCMSCs by immunostaining
assay. As shown in Figure 1C, OCT4 and NANOG,
which represent the pluripotent embryonic stem cell
phenotype, were expressed in hUCMSCs. UCMSCs have
multiple lineages potential to adipogenic and osteogenic
differentiation [13].
To characterize the isolated hUCMSCs in our system,
they were cultured in the adipogenic and osteogenic
complete media. Ten days after induction, osteogenic
differentiation of hUCMSCs was verified as brownish
orange red for extracellular calcium deposits by Alizarin
Red staining (Figure 1D, upper). In addition, accumulationFigure 3 Effect of JNK SP60015 on PARP, cleaved caspase 3, cleaved
of hUCMSCs on PARP, Bax, and cleaved caspase 9 in PC-3 cells. (B) Effect o
p-JNK induced by hUCMSCs in PC-3 cells was detected in immunoblotting
caspase, cleaved PARP, and p-JNK were analyzed by immunofluorescence a
cleaved caspase 3, cleaved PARP, and p-JNK. DAPI (Blue).of lipid vacuoles from the hUCMSCs as the indicator of
adipogenic differentiation of MSCs was detected as
bright red color by Oil-red staining (Figure 1D, lower),
implying that isolated hUCMSCs in this study had stem
cell potential.
hUCMSCs inhibited the proliferation of PC-3 cancer cells
To determine the antitumor effect of hUCMSCs on hu-
man prostate cancer cells, PC-3 prostate cancer cells
(1 × 105) were cocultured with the densities of 3.33 ×
104, 2 × 104, and 1 × 104 of UCMSCs (hUCMSCs:PC-3 s
ratio, 1:10, 1:5, 1:3). First, we determined the viability of
PC-3 cells by MTT assay. The viability of PC-3 cells
cocultured with UCMSCs (hUCMSCs:PC-3, 1:5, 1:3) was
significantly decreased, whereas UCMSCs:PC-3 (1:10)caspase 9, and p-JNK induced by hUCMSCs in PC-3 cells. (A) Effect
f JNK SP60015 on PARP, cleaved caspase 3, cleaved caspase 9, and
assay. (C) In the same condition as in (B), expression levels of cleaved
ssay. Each primary antibody was diluted 1/300. Light green indicates
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cultured without hUCMSCs (Figure 2A). In addition, we
determined the proliferation of PC-3 cells cocultured
with hUCMSCs by BrdU assay. The growth of PC-3 cells
cocultured with hUCMSCs was decreased to 44%, 49%,
and 69% of control in the presence of UCMSCs with
various numbers of 3.33 × 104, 2 × 104, and 1 × 104, re-
spectively, compared with untreated control (Figure 2B).
As shown in Figure 2C, when PC-3 cells were cocul-
tured in the presence of hUCMSCs (UCMSCs:PC-3,
1:3), the number of PC-3 cells was rarely observed com-
pared with untreated control.
hUCMSCs induced apoptosis and attenuated survival
genes in PC-3 cells
To determine whether apoptosis is induced in PC-3 cells
cocultured with hUCMSCs, Western blotting was per-
formed. PARP cleavage, cleaved caspase 3, Bax, and
phosphorylation of JNK were detected in the lysates
of PC-3 cocultured with hUCMSCs (Figure 3A). To
verify whether this apoptotic event is dependent on
JNK pathway, the JNK-specific inhibitor SP600125 was
treated in PC-3 cells cocultured with hUCMSCs. Con-
versely, the apoptotic features such as PARP cleavage,
cleaved caspase 3, and phosphorylation of JNK in PC-3
cells by hUCMSCs were efficiently masked by JNK in-
hibitor SP600125 with Western blotting (Figure 3B) and
immunofluorescence assay (Figure 3C). Also, as shown
in Figure 4A, PI3K and phosphorylation of AKT and
ERK were attenuated in PC-3 cells by hUCMSC cells.Figure 4 Effect of hUCMSCs on survival genes and JNK in PC-3 cells. P
hUCMSCs at the ratio (hUCMSCs:PC-3, 1:3). Cells lysates were immunoblotte
caspase 9, and β-actin antibodies. (A) Effect of hUCMSCs on PI3K, AKT, ERK
cIAP-1, and β-actin in PC-3 cells.Furthermore, the expression of survival genes such as
Bcl-2, Bcl-xL, Survivin, Mcl-1, and cIAP-1 was attenu-
ated in PC-3 cells by Western blotting (Figure 4B).
The homing of hUCMSCs and apoptosis induction in PC-3
cells in nude mouse
Next, we investigated the homing of hUCMSCs to PC-3
cells in mice. PC-3 cells were injected subcutaneously into
the left flank of the Balb-c/nu-nude mice. Two weeks later,
PKH26-labeled hUCMSCs were transplanted into the right
flank of the mice. Mice were killed 7 days after injection.
Immunohistochemistry revealed that hUCMSCs were de-
tected on the PC-3 tumor region with red color by con-
focal microscope (Figure 5A). In addition, TUNEL assay
showed some TUNEL-positive cells in the PC-3 cancer cell
region in mice treated with PKH26-labeled hUCMSCs
(Figure 5B). However, we could not find a significant
inhibitory effect of hUCMSCs on the growth of PC-3
cells for tumor weight and volume in mice compared
with untreated control 3 weeks after PC-3 cell inocula-
tion (data not shown). Thus, we must perform another
animal study with a different number of hUCMSCs via
direct or indirect injection of hUCMSCs into the PC-3
tumor region and check the possibility of teratoma in
mice in the near future.
Discussion
Mesenchymal stem cells (MSCs) are fibroblast-like multi-
potent stem cells that can be differentiated into several cell
types, such as adipocytes, osteocytes, and chondrocytesC-3 cells were cultured for 24 hours alone or in the presence of
d with PI3K, p-AKT, AKT, p-ERK, ERK, p-JNK, JNK and PARP, Bax, cleaved
, and JNK in PC-3 cells. (B) Effect of hUCMSCs on Bcl-2, Bcl-xL, survivin,
Figure 5 Homing of hUCMSCs to PC-3 tumor site in Balb-c/nu-nude mice and their effect on TUNEL-positive cells in PC-3 tumor section.
(A) Paraffin sections for H&E and IHC staining with PKH26 dye (red). The PKH26-labeled cells tracking toward the PC-3 tumor region from the
opposite-side flank. White arrows indicate the labeled PKH26 (red). (B) Representative photographs of TUNEL/PI staining. Red fluorescence
(PKH26) marks transplanted hUCMSCs, and green indicates TUNEL-positive cells. DAPI (blue).
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blood or tissues and adipocytes [34-36]. Although much
evidence suggests that MSCs can be applied to several dis-
eases, such as cancers [1,22,24], cardiac disease [8,37],
stroke [6], and Parkinson and Huntington diseases [3], the
underlying antitumor mechanism of MSCs was not fully
understood until now. Thus, in the current study, the
antitumor signaling of hUCMSCs was elucidated in
PC-3 prostate cancer cells. We isolated hUCMSCs from
umbilical cord tissues and confirmed positive stem cellmarkers, such as OCT4 and NANOG, and successfully in-
duced osteogenesis by Alizarin Red staining and adipogen-
esis by Oil Red O staining, implying that hUCMSCs still
have pluripotency of stem cells to be differentiated into
adipocytes and osteocytes.
In addition, hUCMSCs treatment exhibited cytotoxic
and antiproliferative effects in PC-3 cells by MTT and
BrdU assays, indicating that hUCMSCs target the growth
of PC-3 cells. Similarly, Khakoo et al. [23] supported that
intravenously (i.v.) injected human MSCs home to sites of
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sarcoma, and Chao et al. [24] reported that apoptosis
was noted during coculture of MDA-MB-231 breast can-
cer cells with hUCMSCs. Furthermore, other groups
reported that Z3-MSCs have an inhibitory effect on
tumor growth by secretion of Wnt-inhibitor Dkk1, leading
to downregulation of genes related to the cell cycle
through inhibition of Wnt/β-catenin signaling [38,39].
Our results and other group reports mean that hUCMSC
can be a potential therapeutic approach for the treatment
of cancer. However, the ethical issues should be also
considered, before we use hUCMSC as a therapeutic
approach for tumor treatment.
In general, apoptosis, called programmed cell death,
includes the intrinsic mitochondrial pathway and the
extrinsic cell death pathway [40,41], and the activation
of the JNK pathway is also related to apoptosis [42].
Here, hUCMSCs treatment resulted in the cleavages of
caspase 9/3 and PARP, increased phosphorylation of
JNK and upregulation of Bax as apoptotic protein, and
decreased phosphorylation of PI3K/AKT and ERK in
PC-3 cells by Western blotting, demonstrating the apop-
totic effect of hUCMSCs via mitochondrial and JNK-
dependent pathways. Consistently, hUCMSCs treatment
attenuated the expression of survival genes, such as Bcl-2,
Bcl-xL, Survivin, Mcl-1, and cIAP-1 in PC-3 cells, imply-
ing an inhibitory effect of hUCMSCs on antiapoptotic
proteins.
To confirm the role of JNK in hUCMSCs-induced
apoptosis in PC-3 cells, JNK inhibitor study was carried
out. Conversely, treatment of JNK inhibitor SP600125
reversed the apoptotic ability of hUCMSCs to cleave
caspase 9/3 and PARP in PC-3 cells by Western blotting
and immunofluorescence assay, indicating that the JNK
pathway mediates hUCMSCs-induced apoptosis in PC-3
cells. Consistent with our data, Aikin et al. [43] claimed
that PI3K inhibition led to increased JNK phosphoryl-
ation and pancreas islet cell death, which could be re-
versed by the specific JNK inhibitor SP600125.
Of note, the homing of hUCMSCs to PC-3 cells and
TUNEL-positive cells as an apoptotic feature was de-
tected in the tumor section of PC-3 cells, implying that
hUCMSCs on the left flank can move to PC-3 cells on
the right flank, as the homing of hUCMSCs to PC-3
cells, possibly for cell death. Likewise, Liang et al. [44]
reported that systemically infused hUCMSCs could
home to the inflamed colon and effectively ameliorate
colitis via modulation of IL-23/IL-17 by live in vivo im-
aging and immunofluorescent microscopy.
Overall, our findings demonstrate the antitumor po-
tential of hUCMSCs for PC-3 prostate cancer treat-
ment, but further study is required for animal tumor
study via direct or indirect injection of hUCMSCs in
the near future.Conclusions
Based on our results, UCMSCs inhibit the tumor growth
and have an antitumor potential for PC-3 prostate can-
cer treatment.
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